|
|
|
Insider
Information: |
Heron Patrick J |
Relationship: |
Director, 10% Owner |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
33,463,806 |
|
Indirect Shares
|
27,246,926 |
|
|
Direct
Value |
$748,120,876 |
|
|
Indirect Value
|
$161,263,599 |
|
|
Total
Shares |
60,710,732 |
|
|
Total
Value |
$909,384,475 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
7
|
1
|
Stock
price went up :
|
2
|
0
|
Stock
price went down : |
5
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
25.4%
|
-59.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Trubion Pharmaceuticals, Inc |
TRBN |
10% Owner Indirect, Di... |
|
0 |
2010-10-28 |
0 |
Premium* |
|
Cidara Therapeutics, Inc. |
CDTX |
Director |
2015-04-20 |
0 |
2015-04-20 |
291,023 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
Director |
2015-05-04 |
0 |
2015-05-04 |
2,668,570 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
Director, 10% Owner |
2015-05-12 |
0 |
2015-05-12 |
1,887,332 |
Premium* |
|
Anaptysbio Inc |
ANAB |
10% Owner |
2018-05-11 |
973,612 |
2018-05-11 |
973,612 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2017-02-14 |
8,112,121 |
|
0 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2019-01-18 |
2,571,450 |
|
0 |
Premium* |
|
Aptinyx Inc. |
APTX |
10% Owner |
2018-06-25 |
3,190,079 |
2018-06-25 |
0 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
Director |
2020-07-01 |
9,006 |
2020-07-01 |
1,538,316 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
Director |
2019-07-22 |
0 |
2023-11-09 |
3,728,875 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
2020-06-12 |
5,827,415 |
2020-06-12 |
31,446 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
10% Owner |
2020-01-09 |
1,299,953 |
2020-01-09 |
0 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Director, 10% Owner |
2024-06-14 |
18,826 |
2024-03-04 |
8,808,979 |
Premium* |
|
Passage Bio, Inc. |
PASG |
Director, 10% Owner |
2020-03-03 |
0 |
2020-03-03 |
5,009,219 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
Director |
2020-06-16 |
0 |
2020-06-16 |
2,309,554 |
Premium* |
|
Tarsus Pharmaceuticals, Inc. |
TARS |
10% Owner |
2020-10-20 |
1,917,157 |
2020-10-20 |
0 |
Premium* |
|
Frazier Lifesciences Acquisition... |
FLAC |
Director |
2020-12-11 |
1,000,000 |
2020-12-11 |
0 |
Premium* |
|
Hillevax, Inc. |
HLVX |
Director, 10% Owner |
2024-04-04 |
8,544,187 |
2022-05-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
57 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ARQT |
Arcutis Biotherapeutics, ... |
|
|
2024-03-04 |
4 |
B |
$9.50 |
$199,994 |
I/I |
21,052 |
8,785,284 |
0.01 |
% |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,228,377 |
195,751 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
942,835 |
209,095 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$6,000,000 |
I/I |
400,000 |
88,709 |
1.5 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
733,740 |
733,740 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
2,437,472 |
209,095 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$4,669,365 |
D/D |
311,291 |
311,291 |
2.45 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$1,330,635 |
I/I |
88,709 |
88,709 |
1.5 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-02-02 |
4 |
OE |
$4.55 |
$533,419 |
D/D |
117,235 |
2,345,612 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-02-02 |
4 |
OE |
$4.55 |
$533,419 |
I/I |
117,235 |
2,345,612 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
10% Owner |
|
2017-02-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,112,121 |
|
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,199,011 |
|
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2018-05-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,372,000) |
973,612 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2018-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,372,000) |
973,612 |
0 |
- |
|
APTX |
Aptinyx Inc. |
10% Owner |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,040,079 |
3,040,079 |
0 |
- |
|
APTX |
Aptinyx Inc. |
10% Owner |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
D/D |
150,000 |
3,190,079 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
D/D |
372,439 |
2,571,450 |
2.45 |
- |
|
PHAT |
Phathom Pharmaceuticals, ... |
10% Owner |
|
2019-10-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,877,998 |
|
- |
|
ETTX |
Entasis Therapeutics Hold... |
10% Owner |
|
2020-01-09 |
4 |
S |
$5.00 |
$250,010 |
D/D |
(50,000) |
1,299,953 |
0 |
% |
|
PHAT |
Phathom Pharmaceuticals, ... |
10% Owner |
|
2020-06-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,456,854) |
5,827,415 |
0 |
- |
|
TARS |
Tarsus Pharmaceuticals, I... |
10% Owner |
|
2020-10-20 |
4 |
B |
$16.00 |
$5,000,000 |
D/D |
312,500 |
1,917,157 |
2.45 |
- |
|
TARS |
Tarsus Pharmaceuticals, I... |
10% Owner |
|
2020-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,604,657 |
1,604,657 |
0 |
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
10% Owner Indirect |
|
2010-10-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,237,940) |
0 |
0 |
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
Director |
|
2006-10-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
39,868 |
|
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
Director |
|
2006-10-17 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
105 |
|
- |
|
57 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|